教育经历
· 2003.9 - 2007.7
中国药科大学 - 国家生命科学与技术人才培养基地 - 学士
· 2007.9 - 2010.7
北京协和医学院&清华大学医学部 - 药理学 - 硕士
· 2010.9 - 2013.7
北京协和医学院&清华大学医学部 - 药理学 - 博士
· 2012.3 - 2013.4
美国奥尔巴尼医学中心 - 药理学 - 博士
工作经历
· 2013.9 - 2014.7
肿瘤中心 → 美国佐治亚医学院 → 博士后
· 2014.8 - 2017.3
生化与分子生物学系 → 美国佐治亚医学院 → 博士后
· 2017.1 - 2020.10
美国CheMedImmune公司 → 首席科学家 (兼职)
· 2017.4 - 2020.10
生化与分子生物学系 → 美国佐治亚医学院 → 研究科学家(Junior Faculty Position)
· 2020.11- 至今
生命科学学院 → 天津大学 → 英才副教授、特聘研究员、独立课题组长
研究方向
· 肿瘤表观遗传学
· 肿瘤免疫学与免疫治疗
社会兼职
-
· 2023.6-至今
天津市抗癌协会会员
-
· 2023.3-至今
天津市免疫学会理事
-
· 2022.7-至今
天津市青年科技工作者协会会员
-
· 2021.6-至今
中国免疫学会高级会员
-
· 2021.5-至今
中国抗癌协会青年理事会委员
-
· 2015.1-至今
美国癌症研究学会会员
-
· 2016.1-至今
美国免疫学会会员
个人简介
吕春婉博士于2020年11月加入天津大学生命科学院,近年来已发表学术论文50余篇,获美国授权专利1项,主持一项美国NIH基金项目(已结题)和两项国家自然科学基金项目。主要研究成果以一作/通讯作者发表在ACS Nano,J Natl Cancer Inst (JNCI), J Immunother Cancer, Cancer Immunol Res, Oncogene, Cancer Lett,OncoImmunology等肿瘤免疫学领域权威期刊上,个人H因子28。先后入选天津市“科技咨询专家(青年项目)”和天津大学“北洋学者”英才计划。担任天津市免疫学会理事,Clinical and Translational Medicine,Frontiers in Immunology, Therapeutic Advances in Medical Oncology,Aging等多家权威学术期刊的独立审稿人、英国胰腺癌研究基金(UK Pancreatic Cancer Research Fund)外审专家、国家自然科学基金委员会通讯评审专家和著名免疫学期刊Frontiers in Immunology 副主编。指导学生获得国家奖学金、三好学生、天津大学优秀毕业生,天津大学优秀硕士毕业论文等。主要学术成果总结如下:
本课题组的研究方向和思路是揭示胰腺癌和结直肠癌免疫逃逸和对免疫检查点阻断疗法耐受的分子机制,研发基于分子机制的新型免疫治疗药物,并将其转化至临床试验。如图所示:
一、主持项目
1. 2024年 企业横向项目 结直肠癌免疫治疗药物IFNBCOL01的临床前研究 主持 在研
2. 2022年 国家自然科学基金面上项目 SUV39H1-H3K9me3表观遗传学通路调控结直肠癌的免疫逃逸 主持 在研
3. 2021年 天津市师资队伍建设项目 胰腺癌和结直肠癌免疫逃逸机制研究 主持 已结题
4. 2019年 国家自然科学基金青年项目 肿瘤细胞和MDSCs表达的PD-L1在胰腺癌免疫逃逸中的功能 主持 已结题
5. 2018年 美国国立卫生研究院R43项目 开发神经酰胺类似物作为结肠癌免疫治疗的增强剂 主持 已结题
二、获奖
1. 2024年天津大学优秀硕士学位论文指导教师
2. 2022年国家留学基金委青年骨干教师出国研修项目
3. 2021年天津大学生命科学院第二届青年教师讲课大赛特等奖
4. 2020年天津大学“北洋学者”英才计划
5. 2018年天津市科技咨询专家(青年项目)
6. 2020年美国免疫学会青年科学家旅行奖
7. 2019年美国免疫学会Chambers-Thermo Fisher科学纪念奖
8. 2017年第52届美国东南地区脂质会议优秀口头报告奖
9. 2017年美国免疫学会优秀墙报奖
三、部分科研论文
1. Liyan Liang, Yingcui Yang, Kaidi Deng, Yanmin Wu, Yan Li, Liya Bai, Yinsong Wang, Chunwan Lu*. 2024. Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells. Cells. 2024 Jul 8;13(13):1163. doi: 10.3390/cells13131163. *Corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/38995014/
2. Kaidi Deng, Liyan Liang, Yingcui Yang, Yanmin Wu, Yan Li, Rongrong Zhang, Yulin Tian, Chunwan Lu*. 2024. The Wdr5-H3K4me3 Epigenetic Axis Regulates Pancreatic Tumor Immunogenicity and Immune Suppression. International Journal of Molecular Science. 2024,25(16) 8773; https://doi.org/10.3390/ijms25168773. *Corresponding author at Tianjin University
3. Yingcui Yang, Shixuan Bo, Liyan Liang, Kaidi Deng, Liya Bai, Tao Wang, Yinsong Wang, Kebin Liu and Chunwan Lu*. 2024. Delivery of interferon b-encoding plasmid via lipid nanoparticle restores interferon b expression to enhance anti-tumor immunity in colon cancer. ACS Nano. 2024 Feb 6. Doi: 10.1021/acsnano.3c10972. *Corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/38319978/
该工作被央广网、新华社、中国科技网、科学网、中宏网、健康报、中国教育报等中央媒体追踪报道。
4. Yingcui Yang, Mingqing Zhang, Yongdan Zhang, Kebin Liu, Chunwan Lu*. 2023. 5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL+ Cytotoxic T Lymphocyte Cytotoxicity. Cancers (Basel). 2023 Mar 2;15(5):1563. *Corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/36900354/
5. Chunwan Lu*, Dafeng Yang, John D Klement, Yolonda L Colson, Nicholas H Oberlies, Cedric J Pearce, Aaron H Colby, Mark W Grinstaff, Zhuoqi Liu, Huidong Shi, Han-Fei Ding, Kebin Liu. 2022. H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth. Oncogene, 2022 Apr;41(18):2651-2662. PMCID: PMC9058223
*Co-corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/35351997/
该工作被天津大学英文新闻网追踪报道。
6. Chunwan Lu*, Dafeng Yang, John D Klement, Yolonda L Colson, Nicholas H Oberlies, Cedric J Pearce, Aaron H Colby, Mark W Grinstaff, Han-Fei Ding, Huidong Shi, Kebin Liu. 2022. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. J Immunother Cancer. 10(1):e003543.PMCID: PMC8753452
*Co-corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/35017152/
该工作被天津大学综合新闻网追踪报道。
7. Chunwan Lu*, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel, Thomas Albers, Jennifer L Waller, Huidong Shi, Kebin Liu. 2021. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 9:e002624. PMCID: PMC8323468.
*Co-corresponding author at Tianjin University
https://pubmed.ncbi.nlm.nih.gov/34326167/
该工作被人民日报、科学网、北京日报、津云新闻等媒体报道。
8. Chunwan Lu*, John D Klement, Alyssa D Smith, Dafeng Yang, Jennifer L Waller, Darren D Browning, David H Munn, Kebin Liu. 2020. p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy. J Immunother Cancer. 8:e001365. PMCID: PMC7555101.
*Co-corresponding author
https://pubmed.ncbi.nlm.nih.gov/33051343/
9. Chunwan Lu*, John D Klement, Dafeng Yang, Thomas Albers, Iryna O Lebedyeva, Jennifer L Waller, Kebin Liu. 2020. SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. Cancer Lett. 476:87-96. PMCID: PMC7138631.
*Co-corresponding author
https://pubmed.ncbi.nlm.nih.gov/32061753/
10. Chunwan Lu*, John D. Klement, Wei Xiao, Mohammed Ibrahim, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou, and Kebin Liu. 2019. Type I IFNs activates STAT3 to regulate effector expression of cytotoxic T lymphocyte effectors to suppress tumor development. J Immunother Cancer. 7:157. PMCID: PMC6589175.
*Co-corresponding author
https://pubmed.ncbi.nlm.nih.gov/31228946/
11. Chunwan Lu*, Dafeng Yang, John D. Klement, II Kyu Oh, Natasha M. Savage, Jennifer L. Waller, Aaron H. Colby, Mark W. Grinstaff, Nicholas H. Oberlies, Cedric J. Pearce, Zhiliang Xie, Samuel K. Kulp, Christopher C. Coss, Mitch A. Phelps, Thomas Albers, Iryna O. Lebedyeva, and Kebin Liu. 2019. SUV39H1 represses the expression of cytotoxic T lymphocyte effectors to promote colon tumor immune evasion. Cancer Immunol. Res. 7:414-427. PMCID: PMC6397681.
*Co-corresponding author
https://pubmed.ncbi.nlm.nih.gov/30610059/
该工作被选为当期杂志的封面文章。
12. John D. Klement, Amy V. Paschall, Priscilla S. Redd, Mohammed L. Ibrahim, Chunwan Lu, Dafeng Yang, Esteban Celis, Scott I. Abrams, Keiko Ozato, and Kebin Liu. 2018. An Osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 128:5549-5560. PMCID: PMC6264631.
https://pubmed.ncbi.nlm.nih.gov/30395540/
13. Tsadik Habtetsion, Zhi-Chun Ding, Wenhu Pi, Tao Li, Chunwan Lu, Tingting Chen, Caixia Xi, Helena Spartz, Kebin Liu, Zhonglin Hao, Nahid Mivechi, Yuqing Huo, Bruce R Blazar, David H Munn, Gang Zhou. 2018. Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metab. 28:228-242. PMCID: PMC6082691.
https://pubmed.ncbi.nlm.nih.gov/29887396/
14. Kebin Liu and Chunwan Lu*. 2018. Gut microbes modulate response to immune checkpoint inhibitor cancer immunotherapy. Transl Cancer Res. 7:S608-S610. PMCID: PMC6233902
https://pubmed.ncbi.nlm.nih.gov/30443490/
15. Chunwan Lu*, Dafeng Yang, Maria E. Sabbatini, Aaron H. Colby, Mark W. Grinstaff, Nicholas H. Oberlies, Cedric Pearce, and Kebin Liu. 2018. Contrasting Roles of H3K4me3 and H3K9me3 in Regulation of Apoptosis and Gemcitabine Resistance in Human Pancreatic Cancer Cells. BMC Cancer. 18:149. PMCID: PMC5801751.
https://pubmed.ncbi.nlm.nih.gov/29409480/
16. Chunwan Lu and Kebin Liu. 2017. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Trans Cancer Res. 6:S652-S654. PMCID: PMC6320224.
https://pubmed.ncbi.nlm.nih.gov/30613482/
17. Chunwan Lu, Asif Talukder, Natasha Savage, Nagendra Singh and Kebin Liu. 2017. Jak-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology. 6:e1291106. PMCID: PMC5384417.
https://pubmed.ncbi.nlm.nih.gov/28405527/
18. Chunwan Lu, Amy V. Paschall, Huidong Shi, Natasha Savage, Jennifer L. Waller, Maria E. Sabbatini, Nicholas H. Oberlies, Cedric Pearce, Kebin Liu. 2017. The MLL1-H3K4me3 Axis-Mediated Up-Regulation of PD-L1 Contributes to Pancreatic Cancer Immune Evasion. J Natl Cancer Inst. 109:djw283. PMCID: PMC5291187.
https://pubmed.ncbi.nlm.nih.gov/28131992/
该工作获当期杂志的亮点评论,评论人为美国约翰.霍普金斯大学著名胰腺癌专家Lei Zheng教授。
19. Chunwan Lu, Priscilla S Redd, Jeffrey R Lee, Natasha Savage, and Kebin Liu. 2016. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. OncoImmunology. 5:e1247135. PMCID: PMC5214087.
https://pubmed.ncbi.nlm.nih.gov/28123883/
学术成果
奖励与荣誉
1. 见个人简介